Our portfolio

Descriptor

Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. The Company's lead candidate, AMA0076, targets glaucoma, a condition which damages the optic nerve resulting in vision loss and ultimately blindness.

Developing and commercializing novel therapeutics derived from the innate human immune system to treat a range of infectious and inflammatory diseases. The lead product is currently in phase II clinical trials for acute kidney injury and ulcerative colitis.

Gene-based medicine targeting inherited metabolic disorders, ocular diseases and neurotherapy. The company’s lead product is currently in pivotal trials in patients with lipoprotein lipase deficiency type I.

Biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM)platform. Capable of generating and unparalleled diversity of potent antibodies against a broad range of deseases, the platform allows for more stringent lead selection criteria, thereby increasing the probability of success down the drug development road.

Treatment of metastatic cancers and chronic infections using a proprietary platform technology, involving stimulating immune cells with messenger RNA. The lead programs are in treatment of metastatic renal cell carcinoma and HIV. Argos has a CD83 Soluble Protein for Transplant Rejection/Autoimmune Disorders in late preclinical development.

Formerly known as Genetix Pharmaceuticals Inc.
Gene transfer technology for effective ex vivo human delivery of proprietary genes to treat serious genetic and chronic disorders such as thalassemia, ALD and sickle cell anemia.

Development of medical therapies for inflammatory cardiovascular diseases such as Abdominal Aortic Aneurysms, atherosclerosis and diabetes. The lead program for prevention of AAA growth and rupture is in phase II clinical development.

Curetis AG is a molecular diagnostic company focusing on the development and commercialization of a universal molecular diagnostics solution for easy-to-use, fast and reliable molecular disease testing. First product is the Unyvero P50 Pneumonia Cartridge which provides a single source for both detection of bacteria and antibiotic resistance.

Cellnovo develops and produces the next generation insuline patch pumps with high accuracy, convenience and data logging for diabetes patients.

Focused on the treatment of advanced heart failure patients, CircuLite's microvad system's pump is designed to solve the problems of mechanical failure and blood clotting exhibited in artificial hearts and pumps.

Product-oriented biopharmaceutical company focused on the research and development of new and critical agents for immune modulation. The lead compound recombinant human interleukin-7 is a critical growth factor for T cells with unique features to rebuild the immune system and global enhancement of immune system functions

Diagnostics company developing exosome-based minimally-invasive, body fluid molecular diagnostics for use in detecting and monitoring oncologic, metabolic and other diseases

A biopharmaceutical, start-up company developing novel gastrointestinal drugs. Its flagship drug candidate, GIC-1001, emerges from a series of orally-administered, non-centrally-acting, hydrogen sulphide-releasing opioid agonist providing adequate colonic analgesia to patients undergoing sedation-free colonoscopy.

Hookipa develops a genetic vaccine platform based on a recombinant arenavirus enabling highly efficient immune stimulation with strong T- and B-cell responses. The arenaviral background allows for prime/boost strategies with the same vaccine vector. Hookipa’s lead program is in CMV vaccination.

Insmed (NASDAQ: INSM) is a development stage biopharmaceutical company with expertise in proprietary, advanced liposomal technology designed specifically for inhalation lung delivery. Insmed's lead product ARIKACE liposomal amikacin for inhalation has received FDA and EMEA Orphan Drug designation and finalized phase 2 trials trials in cystic fibrosis and bronchiectasis.

Designs and develops percutaneous transcatheter devices for the treatment of mitral valve regurgitation (a significant factor in congestive heart failure.)

Innovative surgical device company developing BioDynamix™ Anastomosis technology. NiTi markets its ColonRing™ device - the next generation of closure technology for colorectal resection

Oxyrane develops enzyme replacement therapies (ERT) for lysosomal storage diseases (LSDs). Using a proprietary, glycoengineered yeast platform, Oxyrane produces human lysosomal enzymes with high levels of mannose 6-phosphate, the sugar-based targeting mechanism which enables clinically effective product uptake and localisation, facilitating greater efficacy at lower product doses.

PanGenetics is focused on the in-licensing and development of therapeutic antibodies. The lead program has been in a phase II study as chimeric antibody and its humanized counterpart will start clinical testing in 2009.

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins®, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. IND filing for its lead Anticalin PRS-050, a next generation of anti-VEGF drug for the treatment of solid tumours, is expected for end 2009.

Promedior, Inc. is a clinical stage biopharmaceutical company developing novel therapeutics for the treatment of fibrotic and inflammatory diseases. Promedior is developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease; pulmonary fibrosis, scleroderma; and acute and chronic nephropathy.

Provesica develops a novel therapeutic approach to overactive bladder, an area of significant unmet medical need. Its development compound, XEN-D0501, targets a well-established, but not yet exploited mechanism for overactive bladder, and is about to start Phase 2 clinical development.

Pulmagen’s clinical and preclinical pipeline of therapies for chronic respiratory diseases such as COPD, asthma and cystic fibrosis delivers both symptomatic relief (bronchodilators) and a disease modifying effect (anti-inflammatory).

Developing treatments for oncology, based on proprietary third generation RNA chemistry, Locked Nucleic Acid. Santaris’ broad pipeline consists of multiple products in various stages of clinical and preclinical development in cancer, infectious disease and metabolic disorders.

Developing a pipeline of ion channel drugs across a number of indications. Xention is currently undertaking clinical trials in the cardiovascular disease area.